Type 2 diabetes is becoming the leading cause of end-stage renal disease ( ESRD) worldwide. Prevalence of ESRD and the antihypertensive response to renin-angiotensin system intervention are suggested to vary among different ethnicities. the Reduction in Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL) study, which included different ethnic groups, demonstrated a renoprotective effect of losartan. A post hoc analysis from RENAAL was performed where we examined in each ethnic group the ESRD risk, identified independent predictors for ESRD, effect of degree of baseline albuminuria, effect of 6-month antiproteinuric response to therapy on ESRD, and renoprotective effect of losartan assess...
Emerging data show that increased serum uric acid (SUA) concentration is an independent risk factor ...
BACKGROUND: Diabetes causes 45% of incident end-stage renal disease (ESRD). Risk of progression is h...
Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for t...
Type 2 diabetes is becoming the leading cause of end-stage renal disease ( ESRD) worldwide. Prevalen...
Type 2 diabetes is becoming the leading cause of end-stage renal disease (ESRD) worldwide. Prevalenc...
Type 2 diabetes is becoming the leading cause of end-stage renal disease ( ESRD) worldwide. Prevalen...
OBJECTIVE - Asia is predicted to have the largest population of patients with diabetes who are at hi...
OBJECTIVE — Asia is predicted to have the largest population of patients with diabetes who are at hi...
Chronic kidney disease is becoming a public health challenge due to the high risk of progression to ...
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from ...
Background. Diabetic nephropathy has become the single most important cause of end-stage renal disea...
The RENAAL Study is a double-blind, placebocontrolled trial to evaluate the renal protective effects...
Background. Diabetic nephropathy has become the single most important cause of end-stage renal disea...
Angiotensin receptor blockers are renoprotective in hypertensive azotemic patients with type 2 diabe...
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The...
Emerging data show that increased serum uric acid (SUA) concentration is an independent risk factor ...
BACKGROUND: Diabetes causes 45% of incident end-stage renal disease (ESRD). Risk of progression is h...
Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for t...
Type 2 diabetes is becoming the leading cause of end-stage renal disease ( ESRD) worldwide. Prevalen...
Type 2 diabetes is becoming the leading cause of end-stage renal disease (ESRD) worldwide. Prevalenc...
Type 2 diabetes is becoming the leading cause of end-stage renal disease ( ESRD) worldwide. Prevalen...
OBJECTIVE - Asia is predicted to have the largest population of patients with diabetes who are at hi...
OBJECTIVE — Asia is predicted to have the largest population of patients with diabetes who are at hi...
Chronic kidney disease is becoming a public health challenge due to the high risk of progression to ...
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from ...
Background. Diabetic nephropathy has become the single most important cause of end-stage renal disea...
The RENAAL Study is a double-blind, placebocontrolled trial to evaluate the renal protective effects...
Background. Diabetic nephropathy has become the single most important cause of end-stage renal disea...
Angiotensin receptor blockers are renoprotective in hypertensive azotemic patients with type 2 diabe...
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The...
Emerging data show that increased serum uric acid (SUA) concentration is an independent risk factor ...
BACKGROUND: Diabetes causes 45% of incident end-stage renal disease (ESRD). Risk of progression is h...
Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for t...